secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001683168-23-008131
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical reports Q2 net loss down to $3.0M; CEO Fisher replaced by Frakes
--------------------------------------------------------------------------------

- Net loss for fiscal Q2 2023: $3.0M vs $3.8M in prior year; operating expenses decreased 13.4% to $3.2M.
- Cash balance $10.2M as of Sept 30, 2023.
- CEO Charles Fisher replaced by James Frakes (Interim CEO, retains CFO role); Guy Cipriani becomes COO.
- Received DCGI clearance in India for Phase 1 Hemopurifier trial in solid tumors on anti-PD-1 therapy.
- Hemopurifier supply disruption continues; working with FDA for second GNA supplier; new San Diego facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316823008131/0001683168-23-008131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316823008131/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-008131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer